A Study of KC1086 in Patients With Advanced Solid Tumors
ConditionAdvanced Solid Tumors Cancer
Trial statusNot yet recruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18+
SponsorBeijing Konruns Pharmaceutical Co., Ltd.
About this trial
The purpose of this study is to evaluate the safety，tolerability, pharmacokinetics, and preliminary efficacy of KC1086 in participants with advanced recurrent or metastatic solid tumors. The trial will be divided into two parts: dose-escalation phase and dose-expansion phase.
Eligibility criteria
Qualifiers
Histologically or cytologically confirmed recurrent or metastatic solid tumors;
Patients who have failed standard or conventional treatment or for whom no standard treatment is available( definition of treatment failure: intolerable toxic and side effects, disease progression during treatment recurrence after treatment);
Participants with advanced recurrent, unresectable, and/or metastatic tumors must have evaluable or measurable lesions (according to RECIST 1.1)；
Eastern Cooperative Oncology Group performance status score of 0 or 1;
Disqualifiers
Any patient who is known to have untreated central nervous system (CNS) metastasis;
Other kinds of malignancies within 5 years;
Gastrointestinal abnormalities;
Cardiovascular and cerebrovascular diseases;
Trial design
Treatments tested in this trial
- KC1086
Treatment groups
66 Participants
are divided into 1 treatment groupLocations
Sponsors and collaborators
Source ClinicalTrials.gov